Friday, Sep 25, 2020 | Last Update : 01:31 AM IST

184th Day Of Lockdown

Maharashtra126379995603033015 Andhra Pradesh6543855794745410 Tamil Nadu5636915082108871 Karnataka5485574446588331 Uttar Pradesh3588932895945135 Delhi2492592133045014 West Bengal2283021989834421 Odisha184122149379763 Telangana1792461481391070 Bihar169856155824870 Assam159320129130578 Kerala13863398720554 Gujarat1247671051913337 Rajasthan116881972841352 Haryana113075908841177 Madhya Pradesh108167836182007 Punjab99930754092860 Chhatisgarh8618347653680 Jharkhand7267358543626 Jammu and Kashmir65026421151024 Uttarakhand4177729000501 Goa2875322726360 Puducherry2319118065467 Tripura2227215441245 Himachal Pradesh124387836125 Chandigarh102987411123 Manipur9010683859 Arunachal Pradesh7385540813 Nagaland5544445110 Meghalaya4733252838 Sikkim2447190529 Mizoram158510120
  Business   Companies  13 Aug 2020  J&J ties up with Biological E for manufacturing Covid vaccine in India

J&J ties up with Biological E for manufacturing Covid vaccine in India

Published : Aug 13, 2020, 9:02 pm IST
Updated : Aug 13, 2020, 9:02 pm IST

Hyderabad firm ties up to produce J&J's vaccine candidate in India

Mahima Datla, the managing director of Biological E
 Mahima Datla, the managing director of Biological E

Hyderabad: Biological E. Limited, India’s oldest biological products company, said on Thursday that it has tied up US-based Johnson & Johnson to manufacture the latter’s Covid-19 vaccine candidate in India.

“We are very pleased indeed to collaborate with an organisation like Johnson & Johnson. Given the magnitude of the Covid-19 pandemic, our ability to mount an effective response will be predicated on the ability to supply the vaccine globally and in significant quantities. This is best achieved through collaboration,” said Mahima Datla, the managing director of BE.


J&J is developing a vaccine candidate ‘Ad26.COV2.S’ for Coronavirus through its pharmaceutical arm Janssen Pharmaceutica NV. The vaccine candidate is currently in Phase 1/2a clinical trials.

The phase 1/2a study will involve more than 1,000 adults aged between 18 and 55. The study will also include an arm testing the vaccine in people 65 and older. Human trials in the Netherlands, Spain, Germany and Japan will follow.

Johnson & Johnson chief scientific officer Paul Stoffels had told a conference call last month that the company expects initial human results in September and phase 3 efficacy testing could start the same month itself. “The vaccine could be ready by early 2021,” he said.


The tie-up with Biological E. would help J&J to ramp its manufacturing capabilities in India.

“We look forward to deploying our manufacturing infrastructure to support Johnson & Johnson’s commitment to global access for its COVID-19 vaccine,” said Narender Dev Mantena, Director of BioE Holdings Inc., who heads BE’s novel vaccine initiative.

According to the World Health Organisation data, people around the world are working on 42 vaccine candidates for Coronavirus, including two from India, which are at different stages of development.

“Six vaccine candidates are in phase-3 trials, two candidates in phase 2 trials. Ten vaccine candidates, including two being developed in India, are at phase ½,” claims the WHO data as on August 10.


Tags: coronavirus (covid-19), covid vaccine